US20200239449A1 - Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide - Google Patents

Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide Download PDF

Info

Publication number
US20200239449A1
US20200239449A1 US15/767,388 US201815767388A US2020239449A1 US 20200239449 A1 US20200239449 A1 US 20200239449A1 US 201815767388 A US201815767388 A US 201815767388A US 2020239449 A1 US2020239449 A1 US 2020239449A1
Authority
US
United States
Prior art keywords
compound
methyl
crystalline form
temperature
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/767,388
Other languages
English (en)
Inventor
Yanlei Zhang
Michael A. Galella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GALELLA, MICHAEL A., ZHANG, YANLEI
Publication of US20200239449A1 publication Critical patent/US20200239449A1/en
Priority to US17/400,100 priority Critical patent/US12545665B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/04—Mono-, di- or tri-methylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention generally relates to a crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d 3 )pyridazine-3-carboxamide.
  • Compound (I) is disclosed as Example 52 in U.S. Pat. No. 9,505,748 B2, which is assigned to the present assignee. U.S. Pat. No. 9,505,748 B2 also discloses methods of treatment employing Compound (I).
  • Compound (I) is a Tyk2 inhibitor currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis, psoriatic arthritis, lupus, lupus nephritis, Sjögren's syndrome, inflammatory bowel disease, Crohn's disease and ankylosing spondylitis.
  • auto-immune and auto-inflammatory diseases such as psoriasis, psoriatic arthritis, lupus, lupus nephritis, Sjögren's syndrome, inflammatory bowel disease, Crohn's disease and ankylosing spondylitis.
  • the purified compound in a solid form that is physically and chemically stable at a range of storage conditions, such as at different conditions of temperature and humidity.
  • the compound in a solid form that is amenable to additional processing, for example, in which it can be converted into other solids forms, such as an amorphous form.
  • the Applicants have found a crystalline form of Compound (I) that surprisingly provides Compound (I) in a solid form that is physically and chemically stable at a range of storage conditions.
  • Applicants have found a crystalline form of Compound (I) that surprisingly provides Compound (I) in a solid form that is physically and chemically stable at a range of storage conditions and is amenable to additional processing, for example, in which it can be converted into other solids forms, such as an amorphous form.
  • a crystalline form of Compound (I) that surprisingly provides Compound (I) in a solid form that is physically and chemically stable at a range of storage conditions, is amenable to additional processing, for example, in which it can be converted into other solids forms, such as an amorphous form, and has sufficient solubility in solvents/solutions to permit preparation of other solid forms.
  • the present invention is also directed to other important aspects.
  • the present invention provides crystalline Form A of Compound (I).
  • the name used herein to characterize a specific form e.g. “Form A” etc., should not be considered limiting with respect to any other substance possessing similar or identical physical and chemical characteristics, but rather it should be understood that this designation is a mere identifier that should be interpreted according to the characterization information also presented herein.
  • FIG. 2 shows a differential scanning calorimetry (DSC) thermogram of crystalline Form A of Compound (I).
  • FIG. 3 shows a thermogravimetric analysis (TGA) thermogram of the Form A of Compound (I).
  • FIG. 4 shows a moisture-sorption isotherm for Form A of Compound (I) measured at 25° C.
  • polymorphs refer to crystalline forms having the same chemical structure but different spatial arrangements of the molecules and/or ions forming the crystals.
  • amorphous refers to a solid form of a molecule and/or ion that is not crystalline. An amorphous solid does not display a definitive X-ray diffraction pattern with sharp maxima.
  • substantially pure when used in reference to a crystalline form, means a compound having a purity greater than 90 weight %, including greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, and 99 weight %, and also including equal to about 100 weight % of Compound (I), based on the weight of the compound.
  • the remaining material comprises other form(s) of the compound, and/or reaction impurities and/or processing impurities arising from its preparation.
  • a crystalline form of Compound (I) may be deemed substantially pure in that it has a purity greater than 90 weight %, as measured by means that are at this time known and generally accepted in the art, where the remaining less than 10 weight % of material comprises amorphous and/or other form(s) of Compound (I) and/or reaction impurities and/or processing impurities.
  • a powder x-ray diffraction (PXRD) pattern “comprising” a number of peaks selected from a specified group of peaks, is intended to include PXRD patterns having additional peaks that are not included in the specified group of peaks.
  • a PXRD pattern comprising four or more, preferably five or more, 20 values selected from: A, B, C, D, E, F, G, and H, is intended to include a PXRD pattern having: (a) four or more, preferably five or more, 20 values selected from: A, B, C, D, E, F, G, and H; and (b) zero or more peaks that are not one of peaks A, B, C, D, E, F, G, and H.
  • reaction impurities and/or processing impurities may be determined by analytical techniques known in the art, such as, for example, chromatography, nuclear magnetic resonance spectroscopy, mass spectrometry, and/or infrared spectroscopy.
  • unit cell parameter “molecules per unit cell” refers to the number of molecules of Compound (I) in the unit cell.
  • Compound (I) is provided as a crystalline material comprising Form A.
  • the crystalline Form A of Compound (I) is a neat crystalline form.
  • crystalline Form A of Compound (I) is characterized by unit cell parameters approximately equal to the following:
  • crystalline Form A of Compound (I) is characterized by an observed powder x-ray diffraction pattern substantially as shown in FIG. 1 .
  • crystalline Form A of Compound (I) is characterized by an endotherm in the range of from 264° C. to 269° C.
  • crystalline Form A of Compound (I) is characterized by a differential scanning calorimetry (DSC) thermogram substantially as shown in FIG. 2 .
  • crystalline Form A of Compound (I) is characterized by a thermogravimetric analysis (TGA) thermogram having weight loss of less than 0.2%, based on the weight of the sample of Form A, upon being heated to a temperature of about 150° C.
  • TGA thermogravimetric analysis
  • crystalline Form A of Compound (I) exhibits a thermogravimetric analysis (TGA) thermogram substantially as shown in FIG. 3 .
  • crystalline Form A of Compound (I) exhibits a moisture-sorption isotherm substantially as shown in FIG. 4 .
  • crystalline Form A of Compound (I) is substantially pure.
  • the crystalline form of Compound (I) consists essentially of Form A.
  • the crystalline form of this embodiment may comprise at least about 90 wt. %, preferably at least about 95 wt. %, and more preferably at least about 99 wt. %, based on the weight of the crystalline form, Form A of Compound (I).
  • compositions comprising 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d 3 )pyridazine-3-carboxamide, wherein at least 95 wt. %, preferably at least 97 wt. %, and more preferably at least 99 wt.
  • Crystalline forms may be prepared by a variety of methods, including for example, crystallization or recrystallization from a suitable solvent, sublimation, growth from a melt, solid state transformation from another phase, crystallization from a supercritical fluid, and jet spraying.
  • Techniques for crystallization or recrystallization of crystalline forms from a solvent mixture include, for example, evaporation of the solvent, decreasing the temperature of the solvent mixture, crystal seeding a supersaturated solvent mixture of the molecule and/or salt, freeze drying the solvent mixture, and addition of antisolvents (countersolvents) to the solvent mixture.
  • High throughput crystallization techniques may be employed to prepare crystalline forms including polymorphs.
  • solvent for crystallization techniques that employ solvent, the choice of solvent or solvents is typically dependent upon one or more factors, such as solubility of the compound, crystallization technique, and vapor pressure of the solvent. Combinations of solvents may be employed, for example, the compound may be solubilized into a first solvent to afford a solution, followed by the addition of an antisolvent to decrease the solubility of the compound in the solution and to afford the formation of crystals.
  • An antisolvent is a solvent in which the compound has low solubility.
  • a compound is suspended and/or stirred in a suitable solvent to afford a slurry, which may be heated to promote dissolution.
  • a suitable solvent to afford a slurry, which may be heated to promote dissolution.
  • slurry means a saturated solution of the compound, which may also contain an additional amount of the compound to afford a heterogeneous mixture of the compound and a solvent at a given temperature.
  • Seed crystals may be added to any crystallization mixture to promote crystallization. Seeding may be employed to control growth of a particular polymorph or to control the particle size distribution of the crystalline product. Accordingly, calculation of the amount of seeds needed depends on the size of the seed available and the desired size of an average product particle as described, for example, in “Programmed Cooling of Batch Crystallizers,” J. W. Mullin and J. Nyvlt, Chemical Engineering Science, 1971, 26, 369-377. In general, seeds of small size are needed to control effectively the growth of crystals in the batch. Seed of small size may be generated by sieving, milling, or micronizing of large crystals, or by micro-crystallization of solutions. Care should be taken that milling or micronizing of crystals does not result in any change in crystallinity form the desired crystal form (i.e., change to amorphous or to another polymorph).
  • a cooled crystallization mixture may be filtered under vacuum, and the isolated solids may be washed with a suitable solvent, such as cold recrystallization solvent, and dried under a nitrogen purge to afford the desired crystalline form.
  • the isolated solids may be analyzed by a suitable spectroscopic or analytical technique, such as solid-state nuclear magnetic resonance, differential scanning calorimetry, powder x-ray diffraction, or the like, to assure formation of the preferred crystalline form of the product.
  • the resulting crystalline form is typically produced in an amount of greater than about 70 weight % isolated yield, preferably greater than 90 weight % isolated yield, based on the weight of the compound originally employed in the crystallization procedure.
  • the product may be comilled or passed through a mesh screen to delump the product, if necessary.
  • Crystalline forms may be prepared directly from the reaction medium of the final process for preparing Compound (I). This may be achieved, for example, by employing in the final process step a solvent or a mixture of solvents from which Compound (I) may be crystallized. Alternatively, crystalline forms may be obtained by distillation or solvent addition techniques.
  • Suitable solvents for this purpose include, for example, the aforementioned nonpolar solvents and polar solvents, including protic polar solvents such as alcohols, and aprotic polar solvents such as ketones.
  • the presence of more than one polymorph in a sample may be determined by techniques such as powder x-ray diffraction (PXRD) or solid-state nuclear magnetic resonance spectroscopy. For example, the presence of extra peaks in the comparison of an experimentally measured PXRD pattern with a simulated PXRD pattern may indicate more than one polymorph in the sample.
  • the simulated PXRD may be calculated from single crystal x-ray data. See Smith, D. K., “ A FORTRAN Program for Calculating X - Ray Powder Diffraction Patterns ,” Lawrence Radiation Laboratory, Livermore, Calif., UCRL-7196 (April 1963).
  • Form A of Compound (I) may be characterized using various techniques, the operation of which are well known to those of ordinary skill in the art.
  • the forms may be characterized and distinguished using single crystal x-ray diffraction, which is based on unit cell measurements of a single crystal at a fixed analytical temperature.
  • a detailed description of unit cells is provided in Stout & Jensen, X-Ray Structure Determination: A Practical Guide, Macmillan Co., New York (1968), Chapter 3, which is herein incorporated by reference.
  • crystalline structure is by powder x-ray diffraction analysis in which the diffraction profile is compared to a simulated profile representing pure powder material, both run at the same analytical temperature, and measurements for the subject form characterized as a series of 2 ⁇ values (usually four or more).
  • ssNMR solid-state nuclear magnetic resonance
  • differential scanning calorimetry thermal analysis
  • vibrational spectroscopy Other means of characterizing the form may be used, such as solid-state nuclear magnetic resonance (ssNMR), differential scanning calorimetry, thermal analysis, and vibrational spectroscopy. These parameters may also be used in combination to characterize the subject form.
  • Crystalline Form A of Compound (I) can be used to isolate Compound (I) from other components at the completion of the synthesis process; and/or to purify Compound (I) by one or a series of crystallization steps.
  • the isolation and the purification steps can be combined or practiced as separate process steps.
  • 6-chloro-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d 3 )pyridazine-3-carboxamide (1.2 g) was dissolved in 40 mL of dioxane via Rotovap and sonication. After a purge with nitrogen gas for 5 min, 0.6 g of cyclopropanecarboxamide, 0.3 g of Pd 2 (dba) 3 , 0.3 g of XANTPHOS, and 2.1 g of Cs 2 CO 3 were added while still purging. The reaction mixture was heated to 130° C., then filtered and concentrated to remove dioxane.
  • a solution was prepared by mixing 2 g Compound (I) into 143 mL THF and 7 mL water at room temperature (25° C.) until Compound (I) was fully solubilized. The solution was polish filtered at room temperature and then dried overnight using a Speedvac. The resulting solid was suspended in 12 mL of EtOAc at 60° C. and the resulting slurry was aged at 60° C. overnight. The slurry was filtered and the wet cake was washed with 5 mL of EtOAc. The wet cake was dried in a vacuum oven at a temperature in the range of 50-60° C. to afford 1.5 g of Compound (I) in Form A (98.3% purity).
  • a solution was prepared by charging 1.9 g 1-methylimidazole, 17 mL ACN, 3.3 g ( 2 H 3 )methanamine, 17.0 g 6-cyclopropaneamido-4- ⁇ [2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino ⁇ pyridazine-3-carboxylic acid, hemi zinc salt, 17 mL ACN, and 8.5 mL NMP into 34 mL NMP. The solution was heated to 65° C. After aging 1 hour at 65° C., 3.3 g HOBt and 10.3 g EDC HCl were charged to the solution to begin the reaction.
  • the solution was aged for 15 minutes to allow for reaction completion, and then 17 mL of ACN was charged.
  • the newly formed slurry was aged at 65° C. for 30 minutes after which 17 mL of water and 51 mL of ACN was charged.
  • the slurry was cooled to ⁇ 10° C. over 2 hours then aged for 12 hours.
  • the cold slurry was filtered and the crystalline solids were washed with 51 mL of 2:1 water:ACN followed by 51 mL of ACN.
  • the wet cake was dried in a vacuum oven at a temperature in the range of 50-100° C. to afford Compound (I) in Form A.
  • a solution was prepared by mixing 10 g Compound (I) into 55 mL NMP and heating the slurry to 70° C. until Compound (I) was fully solubilized.
  • the solution was polish filtered with the temperature of the batch in the range of 62.5-85° C.
  • the filtrate was warmed up to 70° C. and then 30 mL of IPA was added to the batch.
  • the batch was allowed to return to 70° C., at which point 1 wt % of Compound (I) seeds were added.
  • the newly formed slurry was aged for 1 hour at 70° C. after which 60 mL of IPA was charged to the batch over one hour.
  • the slurry was cooled to ⁇ 10° C. over 3.5 hours.
  • the cold slurry was aged at ⁇ 10° C. for 12 hours.
  • the cold slurry was filtered and the crystalline solids were washed 2 ⁇ 40 mL IPA.
  • the wet cake was dried in a vacuum oven at a temperature in the range of 50-100° C. to afford 8.5 g of Compound (I) in Form A (>99.9 AP purity).
  • the reaction crude was cooled to 20° C.
  • Aqueous acetic acid (50 Volume %, 4.0 kg, 4.0 L/kg) was charged slowly over the course of 1 h. Glacial acetic acid (10.5 kg, 10.0 L/kg) was then added. The resulting homogeneous solution was washed twice with heptane (2 ⁇ 3.42 kg, 2 ⁇ 5.0 L/kg). The bottom aqueous layer was collected and transferred to a clean reactor. Water (5.0 kg, 5.0 L/kg) was added, followed by Compound 9 seeds (0.01 kg, 1.0 wt %). The slurry was aged for 2 h at 20° C. Additional water (2.0 kg, 2.0 L/kg) was added, and the slurry was further aged for 6 h.
  • NMP (2.06 kg, 2.0 L/kg) and ACN (0.78 kg, 1.0 L/kg) were charged to a glass-lined reactor and agitated at 20° C.
  • Compound 13 (0.17 kg, 1.2 equiv.)
  • Compound 9 (1.00 kg) were charged to the reaction mixture.
  • the mixture was heated to 65° C. and aged until homogeneous.
  • EDC HCl (0.54 kg, 1.4 eq
  • the reactor was rinsed with ACN (0.78 kg, 1.0 L/kg), then the resulting mixture was aged at 65° C.
  • reaction was quenched by charging water (1.0 kg, 1 L/kg), then diluted with ACN (3.0 kg, 3 L/kg).
  • ACN 3.0 kg, 3 L/kg
  • the reaction mixture was aged at 65° C. for 1 h, before cooling to 0° C., and aged for an additional 12 h at 0° C.
  • the product was isolated by filtration.
  • the wet cake was washed with 2:1 Water:ACN (2.8 kg, 3 L/kg) then ACN (2.4 kg, 3 L/kg), before drying under full vacuum at 65° C.
  • Compound I was isolated in >99.5% purity and 91% yield.
  • NMP 6.2 kg, 6.0 L/kg
  • Compound I 1.0 kg
  • the batch was heated to 70° C. to form a pale yellow solution, which was then transferred through a polish filter to a clean vessel at 70° C.
  • 2-Propanol 2.4 kg, 3 L/kg
  • Compound I seeds 0.005 kg, 0.005 kg/kg
  • additional 2-propanol 4.8 kg, 6 L/kg
  • the slurry was aged for 1 h at 70° C., cooled slowly to 0° C. and aged for additional 12 h at 0° C.
  • Product was isolated by filtration.
  • the wet cake was washed with 2-propanol (2 ⁇ 3.1 kg, 2 ⁇ 4 L/kg) before drying under full vacuum at 65° C.
  • Compound I was isolated in >99.9% purity and 83% yield.
  • the collected organic layer was diluted with MTBE (4.0 kg, 5.4 L/kg), washed with brine twice (25 wt %, 4.0 kg followed by 12 kg).
  • the organic layer was distilled under vacuum until total volume became approximately 10 L/kg.
  • Two put/take distillations with ACN (2 ⁇ 10 L/kg) were undertaken for the purpose of azeotropic drying.
  • the crude was cooled to 20° C.
  • ACN (10.0 kg, 12.8 L/kg) and NaN(CHO) 2 (3.3 kg, 1.2 equiv.) were added.
  • the crude was heated to 65° C. and agitated until reaction reached completion. After cooling down to 5° C., the mixture was filtered, and the crude cake was washed with ACN twice (2 ⁇ 2.5 kg, 2 ⁇ 3.2 L/kg).
  • the combined filtrates were distilled under vacuum until total volume became approximately 3 L/kg.
  • the crude was cooled to 20° C.
  • Compound 12 was isolated as an oil with 80-85 wt %
  • Samples of micronized Form A of Compound (I) were stored at different conditions of temperature and humidity for 4 weeks.
  • the physical stability characterized by DSC, TGA, and PXRD, were measured at 2 and 4 weeks. No change in the physical form was detected in the samples stored for 4 weeks.
  • the data in Table 2 show that there were no measure change in chemical stability of the samples.
  • Form A of Compound (I) is non-hygroscopic with less than 0.1 weight % gain between 25 to 75% relative humidity at 25° C.
  • Form A of Compound (I) is a non-hygroscopic material, retained good potency, had no significant physical or chemical degradation, and its impurity profiles remain unchanged at the tested temperature and humidity conditions.
  • the single crystal was at room temperature (approximately 25° C.) during data collection.
  • the final unit cell parameters were determined using the full data set.
  • the structures were solved by direct methods and refined by full-matrix least-squares approach using the SHELXTL software package (G. M. Sheldrick, SHELXTL, Bruker AXS, Madison, Wis. USA.).
  • Structure refinements involved minimization of the function defined by ⁇ w(
  • X-ray powder diffraction (PXRD) data were obtained using a Bruker C2 GADDS with Vantec-500 detector. The radiation was Cu K ⁇ (40 KV, 40 mA). The sample-detector distance was ⁇ 20 cm. Incident optics include Goebel mirror and 0.3 mm collimator. Powder samples were placed in sealed glass capillaries of 1 mm or less in diameter; the capillary was rotated during data collection. Data were collected for 2 ⁇ 2 ⁇ 35° with a sample exposure time of at least 1000 seconds. The resulting two-dimensional diffraction arcs were integrated to create a traditional 1-dimensional PXRD pattern with a step size of 0.05 degrees 2 ⁇ in the range of ⁇ 2 to ⁇ 30 degrees 2 ⁇ .
  • DSC Differential scanning calorimetry
  • TGA Thermal gravimetric analysis
  • Moisture-sorption isotherms were collected in a TA Instrument VTI-SA+ Vapor Sorption Analyzer using approximately 10 mg of sample. The sample was dried at 60° C. until the loss rate of 0.0005 wt %/min was obtained for 10 minutes. The sample was tested at 25° C. and 3 or 4, 5, 15, 25, 35, 45, 50, 65, 75, 85, and 95% relative humidity (RH). Equilibration at each relative humidity was reached when the rate of 0.0003 wt %/min for 35 minutes was achieved or a maximum of 600 minutes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
US15/767,388 2017-03-30 2018-03-29 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide Abandoned US20200239449A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/400,100 US12545665B2 (en) 2017-03-30 2021-08-11 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478789P 2017-03-30 2017-03-30
PCT/US2018/025114 WO2018183656A1 (en) 2017-03-30 2018-03-29 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/025114 A-371-Of-International WO2018183656A1 (en) 2017-03-30 2018-03-29 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/400,100 Continuation US12545665B2 (en) 2017-03-30 2021-08-11 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Publications (1)

Publication Number Publication Date
US20200239449A1 true US20200239449A1 (en) 2020-07-30

Family

ID=62002470

Family Applications (5)

Application Number Title Priority Date Filing Date
US15/767,388 Abandoned US20200239449A1 (en) 2017-03-30 2018-03-29 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
US16/498,442 Active US10899745B2 (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
US17/131,718 Active US11649226B2 (en) 2017-03-30 2020-12-22 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl- D3)pyridazine-3-carboxamide
US17/400,100 Active 2040-12-12 US12545665B2 (en) 2017-03-30 2021-08-11 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
US18/134,564 Active US12565487B2 (en) 2017-03-30 2023-04-13 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

Family Applications After (4)

Application Number Title Priority Date Filing Date
US16/498,442 Active US10899745B2 (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
US17/131,718 Active US11649226B2 (en) 2017-03-30 2020-12-22 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl- D3)pyridazine-3-carboxamide
US17/400,100 Active 2040-12-12 US12545665B2 (en) 2017-03-30 2021-08-11 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
US18/134,564 Active US12565487B2 (en) 2017-03-30 2023-04-13 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

Country Status (23)

Country Link
US (5) US20200239449A1 (https=)
EP (4) EP3601268B1 (https=)
JP (6) JP7113023B2 (https=)
KR (4) KR102642407B1 (https=)
CN (4) CN110475774B (https=)
AU (3) AU2018244451B2 (https=)
CA (2) CA3058209A1 (https=)
CY (1) CY1124194T1 (https=)
DK (1) DK3601268T3 (https=)
EA (2) EA201992308A1 (https=)
ES (2) ES2970229T3 (https=)
HR (1) HRP20210764T1 (https=)
HU (1) HUE054886T2 (https=)
IL (3) IL269586B (https=)
LT (1) LT3601268T (https=)
MX (4) MX2019011231A (https=)
PL (1) PL3601268T3 (https=)
PT (1) PT3601268T (https=)
RS (1) RS61816B1 (https=)
SG (2) SG11201909018VA (https=)
SI (1) SI3601268T1 (https=)
SM (1) SMT202100239T1 (https=)
WO (2) WO2018183656A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210107897A1 (en) * 2017-03-30 2021-04-15 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
JP7812785B2 (ja) 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
CN114787152A (zh) * 2019-12-27 2022-07-22 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
WO2021170046A1 (en) * 2020-02-26 2021-09-02 Beigene, Ltd. Tyk-2 inhibitor
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
KR20230042278A (ko) 2020-06-22 2023-03-28 베이진 엘티디 Tyk-2 저해제
CN115667246B (zh) * 2020-07-24 2024-08-23 上海翰森生物医药科技有限公司 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
IL301389A (en) 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores
WO2022083649A1 (zh) * 2020-10-20 2022-04-28 杭州领业医药科技有限公司 哒嗪衍生物的晶型
KR20230137962A (ko) * 2021-01-29 2023-10-05 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
EP4387968B1 (en) 2021-08-20 2025-11-12 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4404930A1 (en) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
JP2024539703A (ja) 2021-10-28 2024-10-29 ブリストル－マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤
EP4441043A1 (en) 2021-12-01 2024-10-09 Teva Czech Industries s.r.o Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
US12222104B2 (en) * 2022-03-21 2025-02-11 General Electric Company Turbine engine combustor and combustor liner
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
CN114989103B (zh) * 2022-06-09 2024-07-09 杭州科巢生物科技有限公司 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法
CN117447411B (zh) * 2022-07-18 2025-12-23 苏州鹏旭医药科技有限公司 一种杂环药物中间体的合成方法
WO2024017150A1 (zh) * 2022-07-18 2024-01-25 苏州鹏旭医药科技有限公司 一种氘可来昔替尼的合成方法
WO2024088282A1 (zh) * 2022-10-28 2024-05-02 浙江华海药业股份有限公司 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途
EP4713315A1 (en) * 2023-05-15 2026-03-25 Alivus Life Sciences Limited Process for the preparation of deucravacitinib, and crystalline forms thereof
EP4538259A1 (en) 2023-10-09 2025-04-16 Farmhispania Group, S.L. Processes for the preparation of deucravacitinib
WO2025131031A1 (zh) * 2023-12-22 2025-06-26 上海奥博生物医药股份有限公司 一种TyK2抑制剂及其中间体的制备方法
WO2025173029A1 (en) * 2024-02-14 2025-08-21 Natco Pharma Limited An improved process for the preparation of deucravacitinib
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
WO2025259267A1 (en) 2024-06-11 2025-12-18 Vector Vitale Ip Llc Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements
ES3059443A1 (es) 2024-09-17 2026-03-20 Moehs Iberica Sl Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074661A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023649B2 (ja) 1976-09-08 1985-06-08 東ソー株式会社 臭化水素酸による臭化メチルの製造方法
JPS5455501A (en) 1977-10-05 1979-05-02 Toyo Soda Mfg Co Ltd Continuous preparation of methyl bromide
US4254061A (en) * 1979-09-11 1981-03-03 E. I. Du Pont De Nemours And Company Preparation of monomethylamine
ATE288420T1 (de) * 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
CA2549385A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes
EP1931466B1 (de) * 2005-09-29 2012-11-14 Basf Se Formkörper enthaltend ein alumosilikat und aluminiumoxid und verfahren zur kontinuierlichen herstellung von methylaminen
KR20090111847A (ko) 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Ｍｅｋ 억제제
BR112012006956A2 (pt) * 2009-10-12 2015-09-15 Bayer Cropscience Ag 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas
EP2542089B1 (en) * 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
JP5433087B2 (ja) * 2010-03-18 2014-03-05 ▲蘇▼州▲澤▼▲ジン▼生物制▲薬▼有限公司 重水素化メチルアミン及びその塩の製造方法
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
WO2013091011A1 (en) * 2011-12-21 2013-06-27 Biota Europe Ltd Heterocyclic urea compounds
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
WO2013171643A1 (en) 2012-05-14 2013-11-21 Piramal Enterprises Limited An improved process for preparation of irbesartan
KR102233252B1 (ko) * 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
JP7631193B2 (ja) * 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
KR20230137962A (ko) * 2021-01-29 2023-10-05 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074661A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210107897A1 (en) * 2017-03-30 2021-04-15 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
US11649226B2 (en) * 2017-03-30 2023-05-16 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl- D3)pyridazine-3-carboxamide
US12565487B2 (en) * 2017-03-30 2026-03-03 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

Also Published As

Publication number Publication date
JP2024037836A (ja) 2024-03-19
WO2018183656A1 (en) 2018-10-04
MX2022010495A (es) 2022-09-21
US20210371404A1 (en) 2021-12-02
AU2018244451B2 (en) 2022-03-10
IL269594B1 (en) 2023-10-01
RS61816B1 (sr) 2021-06-30
JP7457758B2 (ja) 2024-03-28
US12545665B2 (en) 2026-02-10
LT3601268T (lt) 2021-05-25
EP4296258A3 (en) 2024-03-20
SG11201908947QA (en) 2019-10-30
CN116354939A (zh) 2023-06-30
EA201992300A1 (ru) 2020-02-20
AU2018244451A1 (en) 2019-11-21
MX2019011231A (es) 2019-11-18
EP3882237A2 (en) 2021-09-22
MX392693B (es) 2025-03-12
US12565487B2 (en) 2026-03-03
CN116813561A (zh) 2023-09-29
KR102642407B1 (ko) 2024-02-28
US20210107897A1 (en) 2021-04-15
EP4296258A2 (en) 2023-12-27
JP7837938B2 (ja) 2026-03-31
JP7476370B2 (ja) 2024-04-30
PL3601268T3 (pl) 2021-07-05
CA3058209A1 (en) 2018-10-04
JP2020512370A (ja) 2020-04-23
PT3601268T (pt) 2021-04-13
JP2020512380A (ja) 2020-04-23
KR102857398B1 (ko) 2025-09-08
KR20240154690A (ko) 2024-10-25
JP2023052683A (ja) 2023-04-11
CN110914260A (zh) 2020-03-24
JP7260481B2 (ja) 2023-04-18
IL269586A (en) 2019-11-28
CA3058177A1 (en) 2018-10-04
EP3601270A1 (en) 2020-02-05
US20200109134A1 (en) 2020-04-09
KR20190133725A (ko) 2019-12-03
MX2019011092A (es) 2020-01-20
US11649226B2 (en) 2023-05-16
US20230271946A1 (en) 2023-08-31
ES2970229T3 (es) 2024-05-27
CN110475774B (zh) 2023-06-02
IL269594B2 (en) 2024-02-01
EA201992308A1 (ru) 2020-02-13
SG11201909018VA (en) 2019-10-30
JP2022166011A (ja) 2022-11-01
AU2018244916A1 (en) 2019-11-21
EP3882237A3 (en) 2021-11-03
IL269586B (en) 2022-08-01
JP7113023B2 (ja) 2022-08-04
JP2026067880A (ja) 2026-04-21
WO2018183649A1 (en) 2018-10-04
SMT202100239T1 (it) 2021-05-07
ES2864450T3 (es) 2021-10-13
EP3882237B1 (en) 2023-12-20
AU2021261839A1 (en) 2021-12-02
EP3601268A1 (en) 2020-02-05
CN110475774A (zh) 2019-11-19
KR20250080914A (ko) 2025-06-05
DK3601268T3 (da) 2021-05-03
US10899745B2 (en) 2021-01-26
HUE054886T2 (hu) 2021-10-28
MX2022010496A (es) 2022-09-21
IL305615A (en) 2023-11-01
IL269594A (en) 2019-11-28
CY1124194T1 (el) 2022-05-27
BR112019020169A2 (pt) 2020-04-22
AU2021261839B2 (en) 2023-07-20
EP3601268B1 (en) 2021-03-17
AU2018244916B2 (en) 2021-11-18
SI3601268T1 (sl) 2021-07-30
KR20190133726A (ko) 2019-12-03
BR112019020163A2 (pt) 2020-04-22
HRP20210764T1 (hr) 2021-07-09
KR102720054B1 (ko) 2024-10-22

Similar Documents

Publication Publication Date Title
US12545665B2 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
US12291517B2 (en) Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-D3) pyridazine-3-carboxamide
US12570637B2 (en) Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
US12129245B2 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide
US20240190845A1 (en) Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
US20240368130A1 (en) Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3- (1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
EA044397B1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, YANLEI;GALELLA, MICHAEL A.;SIGNING DATES FROM 20180510 TO 20180511;REEL/FRAME:046464/0349

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION